While ADCs are an effective and increasingly common cancer therapy, approval is currently limited to select malignancies (i.e., breast cancer, urothelial cancers, and ovarian cancers) with overall few antigen targets (i.e., TROP2, nectin-4, HER2, tissue factor, and folate receptor alpha1). This evidence concerns the gene TACSTD2 and breast carcinoma.